No Data
Stocks that moved the previous day part2 include Qualipus, Veru Inc, and Sakura Internet, etc.
Stock name <Code> 21-day closing price ⇒ Previous day comparison KADOKAWA＜9468＞ 4170 -218 Reactively strengthened due to Sony's acquisition consideration. ANYCOLOR＜5032＞ 2160 -52 Although there are no specific factors, awareness of the weight on the upside such as the upper wick on the 20th. Torii Yakuhin＜4551＞ 4665 -90 Will profit-taking sales converge in the high price range? Sakura Internet＜3778＞ 4475 -230 NVIDIA leading the way with sell-offs in extended hours trading. Sociownix
Emerging markets stock digest: Agile rebounds, BTM hits the daily limit.
<5247> BTM 1567 +300 stop high. After the close of trading on the 20th, it was announced that in order to accelerate the DX of local companies and municipalities as well as to enter the AI market, a subsidiary specializing in AI technology field will be established, which is viewed positively in terms of material. By leveraging the nationwide talent network cultivated so far in Japan, as well as utilizing the hiring and nurturing capabilities of local talent, an exclusive group of AI engineers will be formed to develop a unique system in the AI field, as well as provide solutions.
Digest of hot stocks (morning session): Foster Electric, Koisaido HD, Axle M, etc.
Foster Electric <6794>: ¥1486 (-¥333) Sharp decline. The company held a briefing on the first half financial results the previous day, as well as announcing the mid-term business plan. In the mid-term plan, the final year March 2028 revenue target is ¥150 billion (¥135 billion forecast for March 2025), operating profit ¥9 billion (¥6.5 billion), aiming for ROE 8.0%, and strengthening shareholder return measures such as increasing the dividend payout ratio to 40% and setting a lower limit of 2% for DOE. However, with limited surprises in the target numbers, 2
Symbio Pharmaceuticals etc continue to rank, set to present research findings at the annual meeting of the USA Hematology Society.
Symbio Pharmaceutical <4582> has ranked in (as of 10:32). It has made a significant rebound. It announced that research results regarding the combination therapy of the injectable Brinsidofovir with immune checkpoint inhibitors for non-Hodgkin lymphoma, conducted in collaboration with the National Cancer Centre Singapore, will be presented at the 66th usa Hematology Conference held from December 7 to 10, which seems to be a key catalyst. Volume change rate leaders [November 21
Volume change rate ranking (9 o'clock) - Koseido HD, Def Consulting and others make the list.
In the ranking of volume change rates, by comparing the average volume of the last five days with the volume on the day of distribution, it is possible to understand the trends in selection and the interests of market participants. ■ Top volume change rates [As of November 21, 9:32] (Comparison of the average volume over the last five days) Stock Code Stock Name Volume 5-Day Average Volume Volume Change Rate Stock Price Change Rate ＜4833＞Def Consulting 5025100 107185.08 288.92% 0.3037% ＜7707
SynBio Pharmaceuticals - announced at the annual meeting of the American Society of Hematology the potential for combination therapy.
Rebound. It is announced that the study results on the potential combination therapy with the immune checkpoint inhibitors of injection drug brincidofovir for non-Hodgkin's lymphoma, conducted in collaboration with the Singapore National Cancer Center, will be presented at the 66th Annual Meeting of the American Society of Hematology, to be held in San Diego, California, USA from December 7th to 10th, and has been well received. Non-Hodgkin's lymphoma is a disease in which lymphocytes become cancerous, including B-cell lymphoma and T-cell lymphoma.
No Data
No Data